<DOC>
	<DOCNO>NCT01659853</DOCNO>
	<brief_summary>The purpose study compare efficacy assess safety CD07805/47 gel 0.5 % apply topically daily versus azelaic acid gel 15 % apply topically twice daily subject moderate severe facial erythema rosacea .</brief_summary>
	<brief_title>Efficacy Safety Study Comparing CD07805/47 Gel 0.5 % Azelaic Acid Gel 15 % Subjects With Erythema Rosacea</brief_title>
	<detailed_description>Adult subject moderate severe facial erythema rosacea meet inclusion/exclusion criterion randomize Baseline/Visit 1 1:1 ratio receive either CD07805/47 gel 0.5 % daily azelaic acid gel 15 % twice daily 15 day . Following appropriate washout period , subject switch treatment use second investigational product instruct 15 day ( accord subject 's randomization scheme ) . Subjects re-qualify base upon inclusion/exclusion prior Period 2 treatment .</detailed_description>
	<mesh_term>Rosacea</mesh_term>
	<mesh_term>Erythema</mesh_term>
	<mesh_term>Brimonidine Tartrate</mesh_term>
	<mesh_term>Azelaic acid</mesh_term>
	<criteria>1 . Subject male female age 18 year old . 2 . Subject clinical diagnosis facial rosacea . 3 . Subject clinician 's assessment score moderate severe erythema prior enrollment . 4 . Subject self assessment score moderate severe redness prior enrollment . 5 . Subjects none mild facial inflammatory lesion rosacea prior enrollment . 1 . Female subject pregnant , nurse plan pregnancy study . 2 . Subjects condition situation , Investigator 's opinion may put subject risk , may confound study result , may interfere subject 's participation study . 3 . Subjects condition cause facial erythema would confound assessment treatment . 4 . Subjects take recently take medication know interaction Î±2adrenergic agonist . 5 . Subjects know allergy sensitivities one component investigational product .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2014</verification_date>
</DOC>